Johnson & Johnson Reaches $230M Settlement With New York To End Sale Of Opioids Nationwide

The company has said that it has not marketed opioids in the U.S. since 2015 and discontinued the business in 2020. JNJ did not admit liability in settling with New York State, Nassau, and Suffolk counties.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.